Private equity firms Acon Investments LLC and Humus Capital Partners LLC acquired a majority stake in Biosidus SA and Biosidus Farma SA.
Buenos Aires, Argentina-based Biosidus develops biosimilars — or identical copies of medicines sold by a different company — with a focus on treating chronic kidney failure, cancer and multiple sclerosis, among others.
Washington, D.C.-based Acon and Buenos Aires-based Humus plan to continue Biosidus' international expansion plan.
Financial terms of the deal were not disclosed.
